AVC-S-101 / Avidicure - LARVOL DELTA

Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) - "The presentation will highlight preclinical data supporting Avidicure’s lead oncology program, AVC-S-101, a TROP2-targeting booster for the treatment of non-small cell lung cancer and several other cancer indications....AVC-S-101 has shown prolonged and significantly improved tumor control in mice models by activating expansion and enhanced cytotoxicity of immune cells. In human non-small cell lung cancer samples freshly isolated from surgically resected tumors, AVC-S-101 demonstrated strong activation of the patient’s own adaptive and innate immune cells, underscoring its potential as a monotherapy for cancer."

Preclinical • Non Small Cell Lung Cancer

Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer (GlobeNewswire) - "Avidicure...today announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures....We are eager to build a broad pipeline with our unique platform and progress our lead oncology product, AVC-S-101, into clinical development for solid tumors....Avidicure’s lead product, AVC-S-101, is a TROP2-targeting booster that is being developed for non-small cell lung cancer and multiple other indications....The company will be presenting preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting in April, and at the American Society of Clinical Oncology (ASCO) Annual Meeting in May."

Financing • Preclinical • Non Small Cell Lung Cancer